Reviva Details Positive Phase 2 Clinical Trial Results for Acute Schizophrenia

 

• Met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective Disorder

• Met primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for Schizophrenia

• Mitigated positive symptoms and negative symptoms

• Improved social functioning and cognition.

• No metabolic (weight gain, elevated blood sugar, increase in lipids), no endocrine (hypothyroidism, hyperprolactinemia) side effects and no increase in suicidal ideation compared to placebo.

https://finance.yahoo.com/news/reviva-announces-full-details-positive-100000492.html